Maidstone Oncology Centre
Welcome,         Profile    Billing    Logout  
 6 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Harper-Wynne, Catherine
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
Summers, Jeff
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Recruiting
N/A
1000
Europe
Royal Marsden NHS Foundation Trust
Colorectal Cancer
07/29
07/31
Hill, Mark
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Recruiting
N/A
1000
Europe
Royal Marsden NHS Foundation Trust
Colorectal Cancer
07/29
07/31

Download Options